Text Size

IUdR/BUdR Cell Cycle Labelling

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00042250
First received: July 24, 2002
Last updated: January 20, 2012
Last verified: January 2012
History of Changes
  Purpose

To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.


Condition Intervention
Hematologic Malignancies
 Drug: Chemotherapy for hematologic malignancy

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by M.D. Anderson Cancer Center:

Enrollment: 28
Study Start Date: May 1992
Study Completion Date: October 2002
Primary Completion Date: October 2002 (Final data collection date for primary outcome measure)
Detailed Description:

Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and differences between normal and leukemic cells in patients with hematologic malignancy prior to and following treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Histologic proof of one of:

  • AML, ALL, or AUL
  • MDS or CMML
  • CML
  • OR undergoing bone marrow transplantation.

Participants should be:

  • off therapy for at least two weeks
  • At least 18 years old or older
  • Using adequate contraception if of child-bearing capability.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00042250

Locations
United States, Texas
M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Study Chair: Michael Andreeff, MD, PhD M.D. Anderson Cancer Center
  More Information

Additional Information:
M. D. Anderson Cancer Center  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00042250     History of Changes
Other Study ID Numbers: DM91-102
Study First Received: July 24, 2002
Last Updated: January 20, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by M.D. Anderson Cancer Center:
Cell Cycle Interphase
G0
G1
G2
S Phase

Additional relevant MeSH terms:
Neoplasms
Hematologic Neoplasms
Neoplasms by Site
Hematologic Diseases

ClinicalTrials.gov processed this record on May 19, 2013